Trial Profile
A study to evaluate whether the reduced calcineurin inhibitor exposure early after liver transplantation protects against renal dysfunction independently of the use of basiliximab induction therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Aug 2015
Price :
$35
*
At a glance
- Drugs Basiliximab (Primary) ; Tacrolimus
- Indications Liver transplant rejection; Renal impairment
- Focus Therapeutic Use
- 12 Aug 2015 New trial record